Skip to main content
Annals of Gastroenterology logoLink to Annals of Gastroenterology
letter
. 2017 Apr 25;30(4):471. doi: 10.20524/aog.2017.0149

The impact of hepatitis C virus and human immunodeficiency virus coinfection on survival in patients with hepatocellular carcinoma

Eleftherios Spartalis a,, Christos Damaskos b, Antonios Athanasiou c, Dimitrios Dimitroulis b
PMCID: PMC5480007  PMID: 28655991

We read with great interest the article by Alkhalili et al [1], who concluded that, despite presenting with more advanced cirrhosis and being less likely to undergo surgery, patients with hepatocellular carcinoma (HCC) associated with viral hepatitis had similar survival to patients with HCC of non-hepatitis B, non-hepatitis C etiology. But do these results reflect the whole picture?

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) share a common route of transmission, so that about one third of HIV infected individuals show HCV co-infection [2]. Highly active antiretroviral therapy has offered a longer and better life to infected patients. While this has removed HIV-related diseases from the list of most common causes of death, their place has been taken by complications of HCV infection, such as cirrhosis, end-stage liver disease, and HCC. HIV-HCV co-infection requires complex management, especially when HCC is present [2]. According to current guidelines, HCC treatment is the same for patients with and without HIV infection, although the outcome seems to be worse for HIV-positive patients than their HIV-negative counterparts [3].

The result of HCV infection is, in the majority of cases, the development of liver cirrhosis. Once cirrhosis is established, the annual risk of HCC, liver disease progression, and death in HCV-infected patients reaches approximately 1-7%, 5%, and 2%, respectively [4]. HIV-HCV coinfected patients have a higher mean rate of fibrosis progression per year, translated into a shorter mean duration from HCV infection to cirrhosis, compared to HCV mono-infected patients [2]. Therefore, as described above, coinfected patients have been shown to develop liver cirrhosis more quickly than HCV-mono-infected individuals and demonstrate a more aggressive course of HCC [5], something that should have been mentioned in this study.

Biography

University of Athens Medical School, Athens, Greece; Mercy University Hospital, Cork, Ireland

Footnotes

Conflict of Interest: None

References

  • 1.Alkhalili E, Greenbaum A, Luo L, et al. Viral hepatitis status does not affect survival in patients with hepatocellular carcinoma. Ann Gastroenterol. 2017;30:101–105. doi: 10.20524/aog.2016.0097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Dimitroulis D, Valsami S, Spartalis E, Pikoulis E, Kouraklis G. Hepatocellular carcinoma in patients co-infected with hepatitis C virus and human immunodeficiency virus. World J Hepatol. 2013;5:323–327. doi: 10.4254/wjh.v5.i6.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.MacDonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol. 2008;14:1657–1663. doi: 10.3748/wjg.14.1657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Singal AK, Anand BS. Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol. 2009;15:3713–3724. doi: 10.3748/wjg.15.3713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med. 2008;59:473–485. doi: 10.1146/annurev.med.59.081906.081110. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Gastroenterology are provided here courtesy of The Hellenic Society of Gastroenterology

RESOURCES